{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:23:10Z","timestamp":1789672990547,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.phrs.2017.09.011","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T12:31:34Z","timestamp":1505910694000},"page":"266-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"PB","title":["Combination drug treatment in hypertension"],"prefix":"10.1016","volume":"125","author":[{"given":"Costas","family":"Tsioufis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas","family":"Thomopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2017.09.011_bib0005","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1056\/NEJMra1203528","article-title":"Behavioral and dietary risk factors for noncommunicable diseases","volume":"369","author":"Ezzati","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.09.011_bib0010","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jama.2013.184182","article-title":"Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries","volume":"310","author":"Chow","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2017.09.011_bib0015","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/HJH.0000000000000988","article-title":"Why in 2016 are patients with hypertension not 100% controlled? A call to action","volume":"34","author":"Redon","year":"2016","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004872-198604000-00003","article-title":"Mortality in patients of the glasgow blood pressure clinic","volume":"4","author":"Isles","year":"1986","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0025","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/00004872-200309000-00011","article-title":"Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population","volume":"21","author":"Benetos","year":"2003","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0030","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels\u2013updated overview and meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/HJH.0000000000001181","article-title":"Blood pressure control in hypertension: pros and cons of available treatment strategies","volume":"35","author":"Mancia","year":"2017","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0021-9681(66)90128-7","article-title":"Effects of treatment in hypertension: results of a controlled study","volume":"19","author":"Wolff","year":"1966","journal-title":"J. Chronic. Dis."},{"key":"10.1016\/j.phrs.2017.09.011_bib0045","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jama.1967.03130240070013","article-title":"Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129mmHg","volume":"202","year":"1967","journal-title":"JAMA"},{"issue":"31","key":"10.1016\/j.phrs.2017.09.011_bib0050","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC)","volume":"2013","author":"Mancia","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0055","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/jhh.2009.76","article-title":"Antihypertensive drug therapy and blood pressure control in men and women: an international perspective","volume":"24","author":"Thoenes","year":"2010","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0060","first-page":"829","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"37","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.09.011_bib0065","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.09.011_bib0070","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.09.011_bib0075","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/01.hjh.0000194120.42722.ac","article-title":"The Felodipine event reduction (FEVER) study: a randomized long-term placebo controlled trial in Chinese hypertensive patients","volume":"23","author":"Liu","year":"2005","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0080","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.09.011_bib0085","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2017.09.011_bib0090","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial","volume":"106","author":"Zanchetti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2017.09.011_bib0095","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.09.011_bib0100","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.09.011_bib0105","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.09.011_bib0110","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.293.6555.1145","article-title":"Randomised trial of treatment of hypertension in elderly patients in primary care","volume":"293","author":"Coope","year":"1986","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2017.09.011_bib0115","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/0140-6736(91)92589-T","article-title":"Morbidity and mortality in the swedish trial in old patients with hypertension (STOP-hypertension)","volume":"338","author":"Dahlof","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.09.011_bib0120","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.09.011_bib0125","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension final results of the systolic hypertension in the elderly program (SHEP)","volume":"265","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2017.09.011_bib0130","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.09.011_bib0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.09.011_bib0140","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am. J. Med."},{"key":"10.1016\/j.phrs.2017.09.011_bib0145","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/HJH.0000000000001052","article-title":"Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0150","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HJH.0000000000000447","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs\u2013overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0155","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/HJH.0000000000000447","article-title":"Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs\u2013overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J. Hypertens."},{"issue":"37","key":"10.1016\/j.phrs.2017.09.011_bib0160","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"2016","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart. J."},{"key":"10.1016\/j.phrs.2017.09.011_bib0165","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2017.09.011_bib0170","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/HJH.0000000000000972","article-title":"Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events\u2014meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjhyper.2003.08.015","article-title":"Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients","volume":"17","author":"Alderman","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0180","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2017.09.011_bib0185","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr039","article-title":"Is a systolic blood pressure target <140mmHg indicated in all hypertensives: subgroup analyses of findings from the randomized FEVER trial","volume":"32","author":"Zhang","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2017.09.011_bib0190","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.09.011_bib0195","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1524-6175.2005.05285.x","article-title":"The effect of antihypertensive drugs on erectile function: a proposed management algorithm","volume":"8","author":"Doumas","year":"2006","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.phrs.2017.09.011_bib0200","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2017.09.011_bib0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jash.2010.06.005","article-title":"Proposal of RAS-diuretic vs.: RAS-calcium antagonist strategies in high-risk hypertension: insight from the 24-hour ambulatory blood pressure profile and central pressure","volume":"4","author":"Kario","year":"2010","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0210","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/jch.12565","article-title":"Resistant hypertension: a real entity or a phantom diagnosis","volume":"17","author":"Thomopoulos","year":"2015","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.phrs.2017.09.011_bib0215","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.09.011_bib0220","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehx215","article-title":"Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: state of the art and considerations for the future","author":"Mahfoud","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2017.09.011_bib0225","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1097\/HJH.0000000000000379","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels\u2013overview and meta-analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0230","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1600177","article-title":"Blood-pressure and cholesterol lowering in persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.09.011_bib0235","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1097\/HJH.0000000000000380","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk-overview and meta-analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0240","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/HJH.0000000000000440","article-title":"Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5\u200amg\/amlodipine 2.5\u200amg as a first-step treatment in hypertension","volume":"33","author":"Laurent","year":"2015","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.09.011_bib0245","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/HJH.0000000000000409","article-title":"et al. Comparison of single-pill strategies first line in hypertension: perindopril\/amlodipine versus valsartan\/amlodipine","volume":"33","author":"Mancia","year":"2015","journal-title":"J. Hypertens."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817310472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817310472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T09:33:25Z","timestamp":1535362405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817310472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":49,"alternative-id":["S1043661817310472"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.09.011","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination drug treatment in hypertension","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}